NCT06352281View on ClinicalTrials.gov

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

December 31, 2027

Conditions
ITP - Immune Thrombocytopenia
Interventions
BIOLOGICAL

CAR-T cells

CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.

Trial Locations (1)

650000

RECRUITING

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming

All Listed Sponsors
lead

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER